A recent experimental study found that EZH2 inhibitor can induce simultaneous upregulation of GPX4 and TfR-1, leading to resistance of DLBCL cells to EZH2 inhibitor. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.